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Adaptive trial designs: what is the continual reassessment method? 
 
Early phase trials provide crucial information about new medicines that allow them to be 
taken forward into larger confirmatory studies. Paediatric early phase studies are becoming 
more common, particularly in the era of precision therapy. There are almost 600 active 
paediatric phase I/II trials listed on clinicaltrials.gov. Conventionally, early phase dose-
escalation trials use rule-based designs such as the 3+3 to guide dose decisions. A trial is 
considered to have a rule-based design if pre-defined rules are used to guide decisions to 
escalate, continue or de-escalate based on the observed toxicities at the current dose.  
  
Though it is well established that model-based design is generally superior to rule-based 
design, its uptake remains low. Trials with a model-based design use statistical models to 
guide decisions on which dose levels to give the next patient(s), based on the targeted 
toxicity level and previous information. In this article, we review one of the most commonly 
used model-based designs, the continual reassessment method. 
 
The goal of any phase I study is to find a recommended dose of a new therapy to advance in 
subsequent studies. This can be defined in different ways; one of the most common being 
the maximum tolerated dose (MTD).  One key question is: “What level of toxicity is 
acceptable based on the expected benefits of treatment?” The MTD is defined as the dose 
expected to cause a degree of medically undesirable dose-limiting toxicity (DLT) in an 
acceptable specified proportion of participants. The latter is referred to as the target toxicity 
level (TTL). This level will differ depending on the expected benefits of the treatment as well 
as the severity of the expected toxicity for the specific intervention. This relationship is 
illustrated in figure 1. 
 
With rule-based 3+3 design, cohorts of three patients are treated at each dose level and 
decisions on escalation or de-escalation are based on the number of patients with DLTs at 
the current dose. If 0/3 patients experience DLTs, the dose is escalated to the next level. If 
1/3 DLT is observed, 3 further patients will be recruited and escalation happens if no further 
DLT is observed. If ≥2/3 DLTs are observed, the dose is de-escalated to the next level. 
Depending on factors such as the number of dose levels and the starting dose, many 
patients may receive sub-therapeutic doses without any toxicities. Other drawbacks are 
highlighted in table 1.[1] 
 
What is the continual reassessment method? 
 
The continual reassessment method is a form of model-based trial design that was first 
proposed in 1990 to obtain the MTD.[2] Unlike rule-based approaches, a continual 
reassessment method utilises a statistical model to estimate the relationship between dose 
and DLT risk. With a Bayesian approach, it integrates accumulated observed data in the trial 
as well as prior information from clinicians and past studies, to recommend a dose with 
estimated DLT risk closest to the TTL to the next cohort/patient. The model learns as the 
trial progresses as the data from every patient already enrolled is included to recommend 
the best MTD estimate for the next patient. Since its introduction, numerous modifications 
have been proposed to improve safety such as increasing the size of dosing cohorts and 
reducing the chance of large increases in dose in the early stages of a study.[3] 
 
continual reassessment method designs are particularly attractive in paediatric trials as it is 
exceptionally rare for a drug to be trialled in children prior to similar studies in adults. The 
toxicity seen in adults can be used to estimate the likely toxicity across the tested doses in 
children to inform an appropriate starting dose and the statistical model. In practice, if we 
observe patients experience DLT at the current dose, the model will assess if it has 
underestimated the risk of DLTs and may then reduce the dose for the next cohort if so. If 
patients do not experience DLT, the opposite may occur.  The trial continues until pre-
defined stopping criteria are met such as a pre-specified maximum number of enrolled 
patients or sufficient patients being dosed at the proposed MTD.[4,5] 
 
Consider Figure 2 from the VIOLA trial. The VIOLA trial was a phase I study looking at the 
treatment of adult patients with relapsed AML post allogeneic stem cell transplant. The 
prior curve shows that the study team initially over-estimated the risk of DLTs. As the trial 
progressed and more patients were treated without DLTs, the model reduced its DLT risk 
estimates, resulting in the updated curves shown.  
 
A good example of a paediatric trial which used the continual reassessment method is a trial 
of selumetinib in patients with recurrent or refractory low grade glioma[6]. 
 
Benefits of continual reassessment method over rule-based designs 
 
A large number of studies have compared continual reassessment method design to rule-
based designs and a number of benefits have been identified, including the ability to 
identify the recommended Phase II dose more accurately. One key advantage is the 
flexibility to accommodate potential deviations from the plan as seen in the VIOLA trial.[7] 
Key features are summarised in table 1.[1,8,9]  
 
 Rule-based designs Model-based designs 
Target DLT rate Unclear Clearly defined and can be flexibly 
chosen 
Patients treated at the optimal dose (relatively) few (relatively) many 
Patients treated at subtherapeutic 
doses 
(relatively) many (relatively) few 
Utilisation of available data Poor Efficient 
Extension to more complex questions Difficult & dubious Smooth & straightforward 
Deviations from the plan (e.g. other 
doses, different number of patients on a 
dose) 
Hard or impossible to 
incorporate 
Easily accommodated 
 
Table 1: Summary of some key features of rule-based and model-based designs[1] 
 
Concerns about continual reassessment method trials 
 
There are some concerns about continual reassessment method studies that currently limit 
their use. All model-based designs account for less than 10% of current phase I studies. They 
are undoubtedly more complex to design/run, requiring active input from a trial statistician. 
This can increase the up-front costs prior to securing funding which can deter some 
clinicians.[10] 
 
Whilst most early phase researchers are readily familiar with the 3+3 design which is simple 
and easy to implement, there can be perceived fears around the “black-box” of model-
based designs. However, it is straightforward to make the “black-box” transparent using the 
concept of “Dose Transition Pathways” to understand possible courses of action in a trial 
that implements a model-based design – both at the design and conduct stage.[11] 
 
Some researchers have raised concerns about the safety of continual reassessment method 
trials. As highlighted in Table 1, continual reassessment method studies are safer and more 
ethical than rule-based designs by treating more patients at a dose more likely to be 
effective whilst protecting them against excessive doses.   Safety mechanisms can be built-in 
to limit risks such as increased dose cohorts and avoid skipping of untried doses in 
escalation. Crucially, these safety mechanisms do not reduce the flexibility or efficiency of 
the studies. Furthermore, the observation of safety data from the first patient in a study 
may be required before any other patients can be dosed in that cohort due to several past 
phase I trial disasters. [5,10,11] 
 
Conclusion 
 
Early phase clinical trials are essential components of evidence-based medicine. Due to 
relatively small patient numbers, it is vital that trials are designed in the most efficient way 
possible. continual reassessment method has been shown to have many advantages over 
conventional trial designs including efficiency and efficacy for patients. Despite this, uptake 
remains low with relatively unfounded fears about the complexity of designing and running 
them. 
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Legends 
 
Figure 1: An illustration of the relationship between dose level and the probability of toxicity and 
activity. A target toxicity level (the proportion of patients in which it is considered acceptable to have 
medically undesirable side effects) of 20% will result in a maximum tolerated dose at dose level 3 
(MTD1), which gives an activity rate (the proportion of patients who demonstrate efficacy) of 45%. A 
target toxicity level of 40% will result in a maximum tolerated dose at dose level 5 (MTD2), which 
gives an activity rate of 70%. The stars indicate the activity at dose level 3 and 5. In this example, as 
the dose increases, the activity increases but so does the toxicity. 
 Figure 2: This figure shows the evolution in the estimates of the probabilities of DLTs through 
successive patient cohorts in the VIOLA trial which utilised a continual reassessment method design. 
The dose-toxicity curves reduced through the first 4 cohorts as no DLTs were observed before 
increasing again in cohorts 5 and 6 when DLTs occurred. The MTD was declared at dose level 3 as it 
had an estimated DLT risk closest to the target toxicity level of 20%. Adapted from: Combination 
Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic 
Stem-Cell Transplantation for Acute Myeloid Leukemia[7] 
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